Medpace (MEDP) Stock: Buy, Sell, or Hold?
MEDP - Medpace Holdings, Inc. Common Stock
$587.52
4.36 (0.75%)
â˛
5d:
-0.99%
30d:
-1.58%
90d:
+23.67%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 28, 2026
Get Alerted When MEDP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MEDP is fairly priced but lacks strong directional signals. At 2.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MEDP is fairly priced but lacks strong directional signals. At 2.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$662.49
Based on 6.6% avg growth
INTRINSIC VALUE TODAY
$411.36
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MEDP is currently trading at $587.52, which is considered slightly low relative to its 30-day fair value range of $584.87 to $609.65. The stock's valuation (Forward PE: 30.4) is in line with its historical norms (28.3). At these levels, the market is pricing in 2.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MEDP is in a strong uptrend. The price is currently testing key support at $577.64. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MEDP scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MEDP is in a strong uptrend. The price is currently testing key support at $577.64. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MEDP scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$584.87 -
$609.65
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.3%
Protect Your Profits
Holding MEDP? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (16/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($581.83)
- NEUTRAL: Market pricing in 2.5% annual earnings growth - fairly valued
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$584.87 -
$609.65
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
Âą$25.62
(4.4%)
Support & Resistance Levels
Support Level
$577.64
Resistance Level
$609.22
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.43
Wall Street Target
$581.83
(-1.0%)
Revenue Growth (YoY)
17.2%
Earnings Growth (YoY)
37.1%
Profit Margin
17.7%
Valuation Premium vs History
+2.5% premium
PE vs Historical
30.4 vs 28.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.5%
(market-implied from PE analysis)
1-Year Target
$602.21
(+3%)
2-Year Target
$617.26
(+5%)
3-Year Target
$632.69
(+8%)
3-Yr Target (if PE normalizes)
(PE: 30â28)
PE COMPRESSION
$588.49
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.4, Growth: 9.1%)
$762.29
(+30%)
Base:
(SPY PE: 20.2, Growth: 9.1%)
$505.34
(-14%)
Bear:
(PE: 17.1, Growth: 9.1%)
$429.54
(-27%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (34x PE), but valuation improves significantly next year (30x PE) as earnings recover.
Trailing PE: 34.49 | Current EPS (TTM): $16.91
Bull Case
$732.52
(+25%)
Analyst growth 14.2%, PE expands to 37.9
Base Case
$665.93
(+13%)
Market implied 14.2%, PE stable at 34.5
Bear Case
$396.55
(-33%)
Severe decline -20.0%, PE contracts to 29.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 13, 2026 6:18 PM ET
Data refreshes hourly during market hours. Next update: 7:18 PM
Data refreshes hourly during market hours. Next update: 7:18 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MEDP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$645 | 51 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$229 | 49 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$196 | 49 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$344 | 47 HOLD |
Advanced MEDP Option Strategies
Professional options setups generated by AI based on today's MEDP price and gamma walls.
